1. Home
  2. UTG vs NAMS Comparison

UTG vs NAMS Comparison

Compare UTG & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reaves Utility Income Fund of Beneficial Interest

UTG

Reaves Utility Income Fund of Beneficial Interest

HOLD

Current Price

$38.33

Market Cap

3.6B

Sector

Finance

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$25.33

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTG
NAMS
Founded
N/A
2019
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.1B
IPO Year
2003
2022

Fundamental Metrics

Financial Performance
Metric
UTG
NAMS
Price
$38.33
$25.33
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$46.75
AVG Volume (30 Days)
236.0K
1.0M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.81
EPS
N/A
N/A
Revenue
N/A
$22,503,000.00
Revenue This Year
N/A
$17.96
Revenue Next Year
N/A
$540.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.81
$23.05
52 Week High
$43.90
$42.21

Technical Indicators

Market Signals
Indicator
UTG
NAMS
Relative Strength Index (RSI) 40.12 38.58
Support Level $37.36 N/A
Resistance Level $38.49 $28.87
Average True Range (ATR) 0.65 0.98
MACD -0.08 -0.04
Stochastic Oscillator 19.08 25.00

Price Performance

Historical Comparison
UTG
NAMS

About UTG Reaves Utility Income Fund of Beneficial Interest

Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: